Uncategorized

Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom

Published

on

After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version